Ashley Hall - Aug 28, 2023 Form 4 Insider Report for Reneo Pharmaceuticals, Inc. (RPHM)

Role: Chief Development Officer
Signature: /s/ Jennifer P. Lam, Attorney-in-Fact
Stock symbol: RPHM
Transactions as of: Aug 28, 2023
Transactions value $: -$69,933
Form type: 4
Date filed: 8/29/2023, 05:04 PM
Previous filing: Dec 13, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RPHM	Common Stock	Options Exercise	$28.1K	+15.6K	+39.46%	$1.80	55.2K	Aug 28, 2023	Direct	F1
transaction	RPHM	Common Stock	Sale	-$98.1K	-15.6K	-28.29%	$6.28	39.6K	Aug 28, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RPHM	Stock option (right to buy)	Options Exercise	$0	-15.6K	-12.5%	$0.00	109K	Aug 28, 2023	Common Stock	15.6K	$1.80	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 4,000 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on June 8, 2023.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.24 to $6.44, inclusive. The reporting person undertakes to provide any security holder of Reneo Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3	The shares vest in a series of 16 equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date.